Karen Smith

Dr. Smith has overseen more than 60 clinical trials and more than 20 regulatory approvals leading to product launches across diverse therapeutic areas including oncology, rare disease, cardiology, dermatology neuroscience and anti-infectives. In addition to R&D and pipeline development, Karen’s successful record of business development includes the acquisition of U.S. and international companies, divestitures and negotiating partnership deals between biotech and pharma. Prior to joining Medeor Therapeutics, Dr, Smith was Chief Executive Officer for Eliminate Cancer (ECI), a cutting-edge oncology R&D and venture organization. Before joining ECI, Karen served as Executive Vice President, Global Head R&D, and Chief Medical Officer of Jazz Pharmaceuticals, Inc., and also held senior leadership positions at Allergan plc, AstraZeneca and Bristol-Myers Squibb. She is currently a member of the Board of Directors of Acceleron Pharma, ECI and Sangamo Therapeutics. Dr. Smith earned an MD from the University of Warwick (UK), PhD in Molecular Oncology from UCLA (USA) and University of Western Australia (Australia), an MBA from the University of New England in Australia and LLM (Masters in Law) from the University of Salford (UK).